Bispecific antibody capable of binding to human CD19 or CD20 and human CD3, and application thereof

Abstract

The invention discloses a bispecific antibody capable of binding to human CD19 or CD20 and human CD3. The bispecific antibody comprises a single-chain antibody domain (scFv), an immunoglobulin G domain (IgG) and an interdomain peptide linker sequence (Link1), and is formed by fusing above three components in one of the following ways: linkage of the carboxyl end of the scFv and the amino end of the light chain of the IgG by the Link1, linkage of the amino end of the scFv and the carboxyl end of the light chain of the IgG by the Link1; linkage of the carboxyl end of the scFv and the heavy chainof the IgG by the Link1, and linkage of the amino end of the scFv and the carboxyl end of the heavy chain of the IgG by the Link1. The invention also discloses a polynucleotide, a vector, a host cell, a medicinal composition related with the bispecific antibody, and a use of the bispecific antibody.

Description

technical field [0001] This article provides an antibody, especially a bispecific antibody capable of simultaneously binding to human CD19 or CD20 and human CD3, and also provides a method for treating related diseases caused by malignant or abnormal B cells. Background technique [0002] B cells play an important role in the body's humoral immune response and antigen presentation. The consequences of B cell lesions are very serious. The diseases caused by them are mainly divided into two categories. The first category is malignant B cell blood cancer, and the second category is autoimmune diseases caused by abnormal B cells recognizing self-antigens. (Janeway et al., Immunobiology: The Immune System in Health and Disease. 5th edition, New York: Garland Science (2001)). [0003] CD19 is a 95kDa transmembrane glycoprotein involved in the regulation of B cell autoimmune response sensitivity (Tedder, Nat.Rev.Rheumatol.5:572-7 (2009); Stanciu-Herrera et al., Leuk.Res.32: 625-3...

AI Technical Summary

Problems solved by technology

[0005] So far, T cell bispecific antibodies have gradually become homogeneous in the application of principles in the treatment of tumors, and it is necessary to improve antibody engineering and molecular design (Bano et al., Antibodies 5:1-23 (2016)), because For example, Blinatumomab, although its molecular structure brings high activity, it also has the disadvantages of short half-life in vivo, low yield and complicated preparation process.

Images